AN 2728 in paediatric and adolescent patients with atopic dermatitis: MUSE trial.
Latest Information Update: 26 May 2020
At a glance
- Drugs Crisaborole (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Pharmacokinetics
- Acronyms MUSE
- 20 May 2020 Results (n=244) assessing systemic exposure parameters of crisaborole with ointment dose and identifing covariates that impact the PK parameters of crisaborole in healthy participants and in patients with AD or psoriasis in 6 studies (C3291010, AN2728-PS-104, NCT01258088; C3291019, AN2728-TQT-108; C3291009, AN2728-PK-101; C3291007, AN27208-AD-203, NCT01652885; C3291006, AN2728-AD-102 & C3291012, AN2728-PSR-106), published in the Journal of Clinical Pharmacology.
- 19 Oct 2015 According to Leo Pharma media release, the US FDA has approved Enstilar for the treatment of plaque psoriasis.
- 13 Nov 2013 New trial record